ClinicalTrials.gg
RecruitingNCT05884814T-REXUpdated Jul 28, 2023

Timing of Resistance Exercise in Type 1 Diabetes

An interventional study of Morning exercise and Afternoon exercise in Type 1 Diabetes, sponsored by Dasman Diabetes Institute. Recruiting at 1 site in Kuwait. Open to participants aged 21 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Dasman Diabetes Institute · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

The aims of the current study are

  1. to compare the effects of acute morning and afternoon resistance exercise on blood glucose levels in people with type 1 diabetes.
  2. to compare the effects of morning and afternoon resistance exercise training on cardiometabolic health outcomes in people with type 1 diabetes
02

Conditions studied

  • Type 1 Diabetes

Keywords

  • exercise
  • circadian rhythm
  • glucose control
  • muscle
  • strength
03

In context

Diabetes Mellitus, Type 1

3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's planned enrollment of 54 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Dasman Diabetes Institute is the lead sponsor of 31 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician confirmed type 1 diabetes for at least 1 year
  • Stable insulin therapy for 3 months prior to the study

Exclusion criteria

Exclusion Criteria:

  • of 45 or higher
  • BP of 160/100mmHg or higher
  • autonomic neuropathy
  • severe proliferative retinopathy
  • joint or limb injuries preventing weight-bearing activity
  • autonomic neuropathy
  • severe proliferative retinopathy
  • any other medical condition that prevents participants from exercising safely.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Placebo comparator
    Control

    Habitual physical activity

    Behavioral: Habitual physical activity levels

  • Active comparator
    Morning exercise

    Exercise training between 6-10am

    Behavioral: Morning exercise

  • Active comparator
    Afternoon exercise

    Exercise training between 4-8pm

    Behavioral: Afternoon exercise

Interventions

  • BehavioralMorning exercise

    Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)

  • BehavioralAfternoon exercise

    Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)

  • BehavioralHabitual physical activity levels

    Participants will be asked to maintain their normal activity levels

06

What researchers measure

Primary outcomes

  1. Change in muscle strength

    Sum of one repetition maximum for the 7 resistance exercise

    Time frame: Change from baseline to 12 weeks

  2. Change in interstitial glucose time in range

    Interstitial glucose time in range (3.9-10mmol/L) measured via continuous glucose monitoring

    Time frame: Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session

Secondary outcomes

  1. Change in appendicular skeletal muscle mass

    Measured by DEXA

    Time frame: Change from baseline to 12 weeks

  2. Change in whole body fat mass

    Measured by DEXA

    Time frame: Change from baseline to 12 weeks

  3. Change in physical function

    Measured by the short performance physical battery

    Time frame: Change from baseline to 12 weeks

  4. Change in HbA1c

    HbA1c concentration

    Time frame: Change from baseline to 12 weeks

  5. Change in interstitial glucose average

    Interstitial average glucose measured via continuous glucose monitoring

    Time frame: Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session

  6. Change in interstitial glucose variability

    Interstitial glucose variability measured via continuous glucose monitoring

    Time frame: Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session

  7. Change in interstitial glucose time in hypoglycaemia

    Interstitial glucose time in range (\<3.9mmol/L) measured via continuous glucose monitoring

    Time frame: Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session

  8. Change in interstitial glucose time in hyperglycaemia

    Interstitial glucose time in range (\>10mmol/L) measured via continuous glucose monitoring

    Time frame: Change from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training session

07

Study locations

1 of 1 sites recruiting
  • Dasman Diabetes Institute
    Kuwait City, 15462, Kuwait
    Recruiting
    • Ebaa AlOZairi · Contact
    • Ebaa AlOzairi · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2024, 17 months after the start.

Of 844 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 17 months is below that.

Counting every sponsor, half of 949 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2023
First posted
Jun 1, 2023
StartActual
Jul 1, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Jul 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05884814
Lead sponsor
Dasman Diabetes Institute
Responsible party
Dr. Ebaa Al Ozairi (Chief Medical Officer, Dasman Diabetes Institute) — Principal investigator
First posted
Jun 1, 2023
Start date
Jul 1, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jul 28, 2023

Study contacts

Ebaa AlOzairi, MBChB
Contact
ebaa.alozairi@dasmaninstitute.rog
+965 22242999

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion